Table 1 General clinical features of T2D patients.
From: Cutoffs of different body measurement indexes of central obesity in patients with type 2 diabetes
Two or more nonadipose components (without WC) by the CDS definition | P-value | ||
|---|---|---|---|
No | Yes | ||
Number of cases (N) | 166 | 891 | |
Age (years) | 58.70 ± 12.42 | 61.09 ± 14.41 | 0.04 |
BMI (kg/m2) | 23.74 ± 3.82 | 25.37 ± 4.21 | < 0.001 |
WC (cm) | 82.95 ± 8.44 | 88.35 ± 9.79 | < 0.001 |
Hip circumference (cm) | 92.56 ± 8.59 | 94.74 ± 8.57 | 0.005 |
Visceral fat area (VFA, cm2) | 70.03 ± 37.75 | 90.45 ± 42.34 | < 0.001 |
Subcutaneous fat area (SFA, cm2) | 160.29 ± 68.13 | 186.92 ± 77.42 | < 0.001 |
Fasting blood glucose (mmol/L) | 7.97 ± 3.44 | 8.00 ± 3.69 | 0.94 |
Fasting C-peptide (μg/L) | 1.74 ± 1.11 | 2.62 ± 1.64 | < 0.001 |
2-h postprandial C-peptide (μg/L) | 4.08 ± 3.43 | 4.85 ± 3.18 | < 0.001 |
HbA1c (%) | 9.90 ± 2.81 | 9.71 ± 2.77 | 0.41 |
Total cholesterol TC (mmol/L) | 4.81 ± 1.07 | 4.75 ± 1.39 | 0.584 |
Triglyceride TG (mmol/L) | 1.05 ± 0.29 | 2.15 ± 2.17 | < 0.001 |
HDL-C (mmol/L) | 1.40 ± 1.05 | 0.98 ± 0.26 | < 0.001 |
LDL-C (mmol/L) | 3.20 ± 1.03 | 3.03 ± 1.16 | 0.09 |
C-peptide insulin resistance index | 1.51 ± 0.00 | 1.51 ± 0.01 | < 0.001 |
C-peptide insulin sensitivity index | 0.08 ± 1.28 | 0.30 ± 1.94 | < 0.001 |
Gender | |||
Female | 91 (54.80%) | 416 (46.70%) | 0.05 |
Male | 75 (45.20%) | 475 (53.30%) | |
Smoking history | |||
No | 142 (85.50%) | 753 (84.50%) | 0.73 |
Yes | 24 (14.50%) | 138 (15.50%) | |
Drinking history | |||
No | 158 (95.20%) | 821 (92.10%) | 0.16 |
Yes | 8 (4.83%) | 70 (7.9%) | |
Education background | |||
Primary school and below | 51 (30.70%) | 237 (26.60%) | 0.36 |
Secondary school | 82 (49.40%) | 493 (55.30%) | |
Junior college or above | 33 (19.90%) | 161 (18.10%) | |
Family history | |||
No | 126 (75.90%) | 666 (74.80%) | 0.75 |
Yes | 40 (24.10%) | 225 (25.30%) | |
Diabetic foot | |||
No | 163 (98.20%) | 860 (96.50%) | 0.26 |
Yes | 3 (1.80%) | 31 (3.50%) | |
Newly diagnosed T2D | |||
No | 114 (68.70%) | 663 (74.40%) | 0.12 |
Yes | 52 (31.30%) | 228 (25.60%) | |
With CKD | |||
No | 146 (88.00%) | 618 (69.40%) | < 0.001 |
Yes | 20 (12.00%) | 273 (30.60%) | |
With retinopathy | |||
No | 158 (95.20%) | 821 (92.10%) | 0.17 |
Yes | 8 (4.80%) | 70 (7.90%) | |
Coronary disease | |||
No | 160 (96.40%) | 766 (86.00%) | < 0.001 |
Yes | 6 (3.60%) | 125 (14.00%) | |
With peripheral vascular disease | |||
No | 110 (66.30%) | 503 (56.50%) | 0.02 |
Yes | 56 (33.70%) | 388 (43.50%) | |
Cerebral infarction | |||
No | 144 (86.80%) | 699 (78.50%) | 0.02 |
Yes | 22 (13.20%) | 192 (21.50%) | |
With peripheral neuropathy | |||
No | 99 (59.60%) | 560 (62.90%) | 0.43 |
Yes | 67 (40.40%) | 331 (37.10%) | |
Hyperuricemia | |||
No | 154 (92.80%) | 711 (79.80%) | < 0.001 |
Yes | 12 (7.20%) | 180 (20.20%) | |
With hypertension | |||
No | 166 (100%) | 319 (35.80%) | < 0.001 |
Yes | 0 (0%) | 572 (64.20%) | |
Fatty liver | |||
No | 119 (71.69%) | 518 (58.14%) | 0.001 |
Yes | 47 (28.31%) | 373 (41.86%) | |
Hypoglycemic regimen | |||
Oral hypoglycemic drugs | 40 (24.10%) | 198 (22.40%) | 0.77 |
Injection of insulin/GLP-1RA | 70 (42.17%) | 399 (45.14%) | |
Oral hypoglycemic drugs + Injection of insulin/GLP-1RA | 56 (33.73%) | 287 (32.47%) | |
